» Articles » PMID: 10051622

In Situ Detection of Activated Bruton's Tyrosine Kinase in the Ig Signaling Complex by Phosphopeptide-specific Monoclonal Antibodies

Overview
Specialty Science
Date 1999 Mar 3
PMID 10051622
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Bruton's tyrosine kinase (Btk) is a critical transducer of signals originating from the B cell antigen receptor (BCR). Dosage, sequential phosphorylation, and protein interactions are interdependent mechanisms influencing Btk function. Phosphopeptide-specific mAbs recognizing two distinct phosphotyrosine modifications were used to quantify Btk activation by immunofluorescent techniques during B cell stimulation. In a population of cultured B cells stimulated by BCR crosslinking and analyzed by flow cytometry, transient phosphorylation of the regulatory Btk tyrosine residues (551Y and 223Y) was detected. The kinetics of phosphorylation of the residues were temporally distinct. Tyrosine 551, a transactivating substrate site for Src-family kinases, was maximally phosphorylated within approximately 30 seconds of stimulation as monitored by flow cytometry. Tyrosine 223, an autophosphorylation site within the SH3 domain, was maximally phosphorylated at approximately 5 minutes. Btk returned to a low tyrosine phosphorylation level within 30 minutes, despite persistent elevation of global tyrosine phosphorylation. Colocalization of activated Btk molecules with the crosslinked BCR signaling complex was observed to coincide with the period of maximal Btk tyrosine phosphorylation when stimulated B cells were analyzed with confocal microscopy. The results of these in situ temporal and spatial analyses imply that Btk signaling occurs in the region of the Ig receptor signaling complex, suggesting a similar location for downstream targets of its activity.

Citing Articles

Droplet-based mRNA sequencing of fixed and permeabilized cells by CLInt-seq allows for antigen-specific TCR cloning.

Nesterenko P, McLaughlin J, Cheng D, Bangayan N, Burton Sojo G, Seet C Proc Natl Acad Sci U S A. 2021; 118(3).

PMID: 33431692 PMC: 7826406. DOI: 10.1073/pnas.2021190118.


p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.

Giordano F, Vaira V, Cortinovis D, Bonomo S, Goedmakers J, Brena F J Exp Clin Cancer Res. 2019; 38(1):260.

PMID: 31200752 PMC: 6570906. DOI: 10.1186/s13046-019-1199-7.


Structural insights into the tyrosine phosphorylation-mediated inhibition of SH3 domain-ligand interactions.

Mero B, Radnai L, Gogl G, Toke O, Leveles I, Koprivanacz K J Biol Chem. 2019; 294(12):4608-4620.

PMID: 30659095 PMC: 6433060. DOI: 10.1074/jbc.RA118.004732.


Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors.

Balasubramanian P, Balupuri A, Kang H, Cho S BMC Syst Biol. 2017; 11(Suppl 2):6.

PMID: 28361711 PMC: 5374705. DOI: 10.1186/s12918-017-0385-5.


Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.

Bogusz A, Baxter R, Currie T, Sinha P, Sohani A, Kutok J Clin Cancer Res. 2012; 18(22):6122-35.

PMID: 22966017 PMC: 5151177. DOI: 10.1158/1078-0432.CCR-12-0397.


References
1.
Kurosaki T . Molecular mechanisms in B cell antigen receptor signaling. Curr Opin Immunol. 1997; 9(3):309-18. DOI: 10.1016/s0952-7915(97)80075-1. View

2.
Guarnieri D, Dodson G, Simon M . SRC64 regulates the localization of a Tec-family kinase required for Drosophila ring canal growth. Mol Cell. 1998; 1(6):831-40. DOI: 10.1016/s1097-2765(00)80082-9. View

3.
Dingjan G, Maas A, Nawijn M, Smit L, Voerman J, Grosveld F . Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase. EMBO J. 1998; 17(18):5309-20. PMC: 1170858. DOI: 10.1093/emboj/17.18.5309. View

4.
Satterthwaite A, Lowell C, Khan W, Sideras P, Alt F, Witte O . Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways. J Exp Med. 1998; 188(5):833-44. PMC: 2213392. DOI: 10.1084/jem.188.5.833. View

5.
Powis G, Bonjouklian R, Berggren M, Gallegos A, Abraham R, Ashendel C . Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 1994; 54(9):2419-23. View